Professor Emily Simonoff
+44 (0)20 7848 5312
Professor Emily Simonoff is the lead of our Child and Developmental Disorders theme.
I am Professor of Child and Adolescent Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London, and also head of the Department of Child and Adolescent Psychiatry. I studied Psychology and Social Relations and then Medicine at Harvard University, and after qualifying I trained at the Maudsley Hospital.
Following a Wellcome Training Fellowship, I joined the MRC Child Psychiatry Unit where I became a Senior Scientist. I was appointed Professor at Guy’s King’s and St Thomas’ Hospital Medical school in 1998 and at the Institute of Psychiatry in 2002. I am the academic lead for the Child Mental Disorders Clinical Academic Group in King’s Health Partners, the academic health sciences centre for King’s College London.
My clinical and research interests focus on the interface among neurodevelopmental disorders, especially autism, ADHD and intellectual disability. My research is cited in 4 NICE guidelines, and I am the Coordinator of the European ADHD Guidelines Group.
BA summa cum laude in Psychology & Social Relations, Harvard University, USA
MD, Harvard Medical School, USA
FRCPsych (Fellow of the Royal College of Psychiatrists)
I lead the Child Mental Disorders theme within the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London.
The work of this theme focuses on (1) developing novel interventions for child mental disorders, especially complex presentations of multiple disorders and demonstrating feasibility/pilot efficacy; (2) developing patient –specific treatment targets for use in routine treatment; (identifying biomarkers for stratification and (3) development of the ePJS/CRIS interface to improve routine outcome measurement.
My own research focusses on autism, ADHD and intellectual disability, and the presentation of common mental health problems in these patient groups. This includes the identification of biomarkers for diagnosis and treatment stratification and the development of novel interventions to target additional mental health concerns.